The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Initiative aimed at enhancing workforce skills and competency in line with industry standards so as to create a talented workforce for the Fourth Industrial Revolution
Venus Remedies secures marketing authorization in Philippines
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Indoco Remedies has reported total income of Rs. 434.22 crores during the period ended September 30, 2024
Indoco is comprehensively working on the remedial action plan
Cetirizine is used for relief of symptoms of hay fever and other allergic conditions
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
Subscribe To Our Newsletter & Stay Updated
